Latest News and Press Releases

WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter...

Tevogen evaluates acquisition of Sciometrix to build integrated clinical infrastructure and advance its 2026 revenue goals.

Tevogen evaluates acquisition of Sciometrix to build integrated clinical infrastructure and advance its 2026 revenue goals.

Tevogen said its Board will evaluate a potential one-time special cash dividend, contingent on future revenue and earnings milestones and Board approval.

Tevogen announced changes to its long-term stock-based incentive program, aligning awards with company milestones, including revenue.

Tevogen reports 2025 progress advancing its scalable ExacTcell platform, expanding multi-indication CTL programs, and strengthening manufacturing readiness

WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable...

WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000...

WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of...

Tevogen honors Board Member Dr. Curtis Patton as Yale recognizes his distinguished career, underscoring the Company’s ongoing growth.